Demeter and Emertec inject €1.8m into Ynsect

Private investors also took part in the round. Emertec contributed half of the fresh capital, investing via the €47.5m Emertec 5 fund. Demeter drew capital from the Demeter 3 Amorçage vehicle, which held a €43m first close in late 2012.

The round of funding will allow Ynsect to keep up with its R&D efforts, develop its production pilot and eventually target its first markets.

Company
Established in late 2011, Ynsect operates a large-scale insect farm, with a view to develop new molecules for several markets. These include cosmetics and speciality chemicals, and will ultimately encompass nutrition and the general food sector.

Both investors stated they had been attracted by the renewable aspect of Ynsect's business model.

People
Franck Lamy led the deal for Emertec. Demeter was represented by Olivier Dupont.

Advisers
Equity – Joffe & Associés, Thomas Saltielle, Virginie Belle (Legal); PKF, Sylvain Lavagnat (Financial due diligence).
Company – Kahn & Associés, Olivier Cognard, Lien Le (Legal).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• France
• Early-stage
• Healthcare
• Demeter Partners
• France